Kappa/Lambda Light-chain Typing in Alzheimer’s Disease


Kaya Z. Z. , Tuzuner M. B. , Sahin B., Akgun E., Aksungar F. , Koca S., ...More

Current Alzheimer Research, vol.19, no.1, pp.84-93, 2022 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.2174/1567205019666220131101334
  • Title of Journal : Current Alzheimer Research
  • Page Numbers: pp.84-93
  • Keywords: Affinity capture resins, Alzheimer's disease, Kappa light chain, Lambda light chain ratio, MALDI-TOF-MS, Microaffinity chromatography, Ratio, Screening tool

Abstract

© 2022 Bentham Science Publishers.Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease. Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnos-ing Alzheimer's disease, which can significantly reduce the cost and time of existing methods. Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (κ) and lambda (λ) light chain levels in control and patients with AD. Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (κLC/λLC) ratios between patients with AD and controls (mean difference-0,409; % 95 CI:-0.547 to-0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls. Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining κLC/λLC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.